Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RISANKIZUMAB vs RISPERDAL: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RISANKIZUMAB vs RISPERDAL: Safety Overview

Metric RISANKIZUMAB RISPERDAL
Total FAERS Reports 2,642 530
Deaths Reported 41 53
Death Rate 1.6% 10.0%
Hospitalizations 439 235
Average Patient Age 52.1 yrs 44.7 yrs
% Female Patients 51.3% N/A
Manufacturer AbbVie Inc. N/A
Route SUBCUTANEOUS N/A